These results demonstrate that both pain interference score and pain intensity are significant predictors of overall survival in men with castrate-refractory prostate cancer. Furthermore, pain interference score and pain intensity are statistically significant predictors of overall survival even when adjusting for established prognostic factors. It is known that high levels of alkaline phosphatase, PSA, and lactate dehydrogenase; low levels of hemoglobin; and high Gleason scores are indicators of advanced progression and death. Thus, these findings support the hypothesis that pain intensity and pain interference score are validated measures of advanced disease in men with prostate cancer. We agree with Klepstad and Kaasa in that investigating the relationship between pain and clinical outcomes in cancer patients is a fruitful area of research. 
6,7 Nevertheless, among patients with wild-type KRAS CRC, the objective response rate is limited to 17% (v 0% in unselected patients) with panitumumab monotherapy 8 and to 59% and 61% (v 43% and 33% in unselected patients) with cetuximab plus either irinotecan-or oxaliplatin-based chemotherapy, respectively. 9, 10 These data indicate that other mechanisms of resistance play a significant role. Moreover, evaluation of metastatic rather than primary sites could be of clinical relevance because occurrence of a mutation in the metastasis could, at least theoretically, explain resistance despite a wild-type primary tumor. Scarce and heterogeneous reports have evaluated whether KRAS status matches in primary tumor and metastatic site(s), [11] [12] [13] [14] whereas BRAF remains unexplored. For these reasons, we elected to evaluate KRAS (exon 2) and BRAF (exon 15) by DNA sequencing in a cohort of 48 CRC patients (median age, 56 years; range, 37 to 79 years; 28 men and 20 women) in primary tumor (colon, n ϭ 32; rectum, n ϭ 7; and sigma-rectum junction, n ϭ 9) and matched metastases (liver, n ϭ 39; ovary, n ϭ 2; distant lymph nodes, n ϭ 1; adrenal gland, n ϭ 1; pancreas, n ϭ 1; lung, n ϭ2; omentum, n ϭ 1; and pelvic mass, n ϭ 1). DNA sequencing showed a frequency of mutation in the primary tumor or metastases of 13 (27%) of 48 and two (4%) of 48 patients for KRAS and BRAF, respectively. None of the patients carried both mutations (in primary tumor or metastasis); the occurrence of the mutations was a mutually exclusive phenomenon, as expected by literature. 15 We observed an overall concordance of KRAS and BRAF mutational status (ie, mutated or wild type) between primary tumor and metastasis in 44 (92%) of 48 patients. In patients carrying a KRAS mutation, concordance between primary tumor and secondary deposits was observed in 10 (77%) of 13 patients, all but one of whom presented with synchronous metastases (Table 1) . Discordance of KRAS mutational status was detected in three (23%) of 13 patients with mutations, with one patient carrying KRAS mutation in the primary tumor only and two patients carrying the mutation in the metastatic site only (pancreas and adrenal gland). Notably, occurrence of KRAS mutations with wild-type primary tumor was detected in extrahepatic sites only. In the two patients carrying BRAF mutation, one patient presented the same mutation in both primary tumor and metastasis, whereas the other patient presented the mutation in the primary tumor site only.
Controversial and heterogeneous previous reports 11-14 demonstrated overall concordance between KRAS mutations in the primary tumor and secondary deposits in CRC, indicating that KRAS mutations are not essential for the attainment of metastatic capacity. In a previous study, Oudejans et al 11 evaluated 39 patients and found, in three patients, a KRAS point mutation in the metastasis with a wild-type primary tumor, whereas in a single patient, a point mutation was found in a primary tumor but was absent from the metastasis. Moreover, these investigators did not find differences in frequency of KRAS mutations between 23 patients with isolated lung metastases and 20 patients with liver metastases (57% and 50%, respectively), demonstrating that KRAS oncogene activation does not have a major role in determining the frequency of lung metastases versus liver metastases. Suchy et al 12 demonstrated the concordance of KRAS mutations in primary tumors and respective metastases in 15 patients, and the type of mutation was also identical in the instance of different metastases from the same primary tumor localized in different organs, indicating a stability of these mutations during metastatic progression. In a series from 1998, Al-Mulla et al 13 reported that only two (8%) of 26 metastatic patients had a mutation in their primary carcinoma but none in liver metastases. In contrast with these data showing overall identity of KRAS mutations between primary tumor and matched metastatic deposits, Tó rtola et al 14 described discordance between KRAS mutation in bone marrow micrometastases and primary tumor. In particular, in six patients with primary tumor mutations, the pattern of KRAS mutation differed in three patients, and in one patient the same mutation plus a different one were found; moreover, in eight patients, there was a mutation in the primary tumor and none in bone marrow metastases. In the present cohort, we took into consideration KRAS and BRAF mutations because alterations of both of these cellular effectors can impair response to anti-EGFR therapy. For both genetic alterations, we observed overall concordance between primary tumor and metastasis in the vast majority of patients. Present findings represent additional knowledge supporting the notion that a concordance of KRAS and BRAF status is the most common feature in CRC. The clinical relevance of these data is that evaluation of the KRAS and BRAF mutations can be performed in either primary tumor or metastatic site(s) and that absence of such mutations could be enough to drive the selection of metastatic CRC patients who are candidates for anti-EGFR monoclonal antibody therapy. 
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